NRIX Live signaler | Maksimer profitt med Getagraph.com

KJøP 106134 min ago

@ $9.02

Utstedt: 14 feb 2024 @ 20:04

Avkastning: 37.03%

Forrige signal: feb 14 - 15:30

Forrige signal: Selg

Avkastning: 0.89 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders...

Stats
Dagens volum	599 462
Gjennomsnittsvolum	1.02M
Markedsverdi	733.16M
EPS	$0 ( 2024-04-11 )
Neste inntjeningsdato	( $-0.720 ) 2024-07-11
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.65
ATR14	$0.0200 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-16	Van Houte Hans	Sell	6 812	Common Stock
2024-02-13	Van Houte Hans	Buy	150 000	Employee Stock Option (right to buy)
2024-02-13	Van Houte Hans	Buy	45 000	Restricted Stock Units
2024-02-13	Ring Christine	Buy	150 000	Employee Stock Option (right to buy)
2024-02-13	Ring Christine	Buy	45 000	Restricted Stock Units

INSIDER POWER
91.86
Last 100 transactions
Buy: 2 499 418 \| Sell: 108 263

Volum Korrelasjon

Lang: -0.44 (neutral)

Kort: 0.37 (neutral)

Signal:(51.965) Neutral

Nurix Therapeutics, Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Nurix Therapeutics, Inc. Korrelasjon - Valuta/Råvare

0.08
( neutral )

0.32
( neutral )

0.00
( neutral )

-0.18
( neutral )

0.09
( neutral )

-0.35
( neutral )

Nurix Therapeutics, Inc. Økonomi

Annual	2023
Omsetning:	$76.99M
Bruttogevinst:	$63.33M (82.26 %)
EPS:	$-2.65

FY	2023
Omsetning:	$76.99M
Bruttogevinst:	$63.33M (82.26 %)
EPS:	$-2.65

FY	2022
Omsetning:	$38.63M
Bruttogevinst:	$27.82M (72.02 %)
EPS:	$-3.42

FY	2021
Omsetning:	$29.75M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.64

Financial Reports:

No articles found.

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.